These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

487 related articles for article (PubMed ID: 32457127)

  • 1. NKTR-214 immunotherapy synergizes with radiotherapy to stimulate systemic CD8
    Walker JM; Rolig AS; Charych DH; Hoch U; Kasiewicz MJ; Rose DC; McNamara MJ; Hilgart-Martiszus IF; Redmond WL
    J Immunother Cancer; 2020 May; 8(1):. PubMed ID: 32457127
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Combining bempegaldesleukin (CD122-preferential IL-2 pathway agonist) and NKTR-262 (TLR7/8 agonist) improves systemic antitumor CD8
    Rolig AS; Rose DC; McGee GH; Rubas W; Kivimäe S; Redmond WL
    J Immunother Cancer; 2022 Apr; 10(4):. PubMed ID: 35444059
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Combination of radiation therapy, bempegaldesleukin, and checkpoint blockade eradicates advanced solid tumors and metastases in mice.
    Pieper AA; Rakhmilevich AL; Spiegelman DV; Patel RB; Birstler J; Jin WJ; Carlson PM; Charych DH; Hank JA; Erbe AK; Overwijk WW; Morris ZS; Sondel PM
    J Immunother Cancer; 2021 Jun; 9(6):. PubMed ID: 34172518
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Abscopal Effects With Hypofractionated Schedules Extending Into the Effector Phase of the Tumor-Specific T-Cell Response.
    Zhang X; Niedermann G
    Int J Radiat Oncol Biol Phys; 2018 May; 101(1):63-73. PubMed ID: 29534901
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Modeling the receptor pharmacology, pharmacokinetics, and pharmacodynamics of NKTR-214, a kinetically-controlled interleukin-2 (IL2) receptor agonist for cancer immunotherapy.
    Charych D; Khalili S; Dixit V; Kirk P; Chang T; Langowski J; Rubas W; Doberstein SK; Eldon M; Hoch U; Zalevsky J
    PLoS One; 2017; 12(7):e0179431. PubMed ID: 28678791
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bempegaldesleukin selectively depletes intratumoral Tregs and potentiates T cell-mediated cancer therapy.
    Sharma M; Khong H; Fa'ak F; Bentebibel SE; Janssen LME; Chesson BC; Creasy CA; Forget MA; Kahn LMS; Pazdrak B; Karki B; Hailemichael Y; Singh M; Vianden C; Vennam S; Bharadwaj U; Tweardy DJ; Haymaker C; Bernatchez C; Huang S; Rajapakshe K; Coarfa C; Hurwitz ME; Sznol M; Hwu P; Hoch U; Addepalli M; Charych DH; Zalevsky J; Diab A; Overwijk WW
    Nat Commun; 2020 Jan; 11(1):661. PubMed ID: 32005826
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hypofractionated radiotherapy combined with lenalidomide improves systemic antitumor activity in mouse solid tumor models.
    Onyshchenko K; Luo R; Rao X; Zhang X; Gaedicke S; Grosu AL; Firat E; Niedermann G
    Theranostics; 2024; 14(6):2573-2588. PubMed ID: 38646638
    [No Abstract]   [Full Text] [Related]  

  • 8. Combination of vasculature targeting, hypofractionated radiotherapy, and immune checkpoint inhibitor elicits potent antitumor immune response and blocks tumor progression.
    Pierini S; Mishra A; Perales-Linares R; Uribe-Herranz M; Beghi S; Giglio A; Pustylnikov S; Costabile F; Rafail S; Amici A; Facciponte JG; Koumenis C; Facciabene A
    J Immunother Cancer; 2021 Feb; 9(2):. PubMed ID: 33563772
    [TBL] [Abstract][Full Text] [Related]  

  • 9. NKTR-214, an Engineered Cytokine with Biased IL2 Receptor Binding, Increased Tumor Exposure, and Marked Efficacy in Mouse Tumor Models.
    Charych DH; Hoch U; Langowski JL; Lee SR; Addepalli MK; Kirk PB; Sheng D; Liu X; Sims PW; VanderVeen LA; Ali CF; Chang TK; Konakova M; Pena RL; Kanhere RS; Kirksey YM; Ji C; Wang Y; Huang J; Sweeney TD; Kantak SS; Doberstein SK
    Clin Cancer Res; 2016 Feb; 22(3):680-90. PubMed ID: 26832745
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A First-in-Human Study and Biomarker Analysis of NKTR-214, a Novel IL2Rβγ-Biased Cytokine, in Patients with Advanced or Metastatic Solid Tumors.
    Bentebibel SE; Hurwitz ME; Bernatchez C; Haymaker C; Hudgens CW; Kluger HM; Tetzlaff MT; Tagliaferri MA; Zalevsky J; Hoch U; Fanton C; Aung S; Hwu P; Curti BD; Tannir NM; Sznol M; Diab A
    Cancer Discov; 2019 Jun; 9(6):711-721. PubMed ID: 30988166
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Combinatorial immunotherapy induces tumor-infiltrating CD8
    Van Braeckel-Budimir N; Dolina JS; Wei J; Wang X; Chen SH; Santiago P; Tu G; Micci L; Al-Khami AA; Pfister S; Ram S; Sundar P; Thomas G; Long H; Yang W; Potluri S; Salek-Ardakani S
    J Immunother Cancer; 2021 Dec; 9(12):. PubMed ID: 34903555
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cross-presentation of tumor antigens to effector T cells is sufficient to mediate effective immunotherapy of established intracranial tumors.
    Plautz GE; Mukai S; Cohen PA; Shu S
    J Immunol; 2000 Oct; 165(7):3656-62. PubMed ID: 11034369
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bempegaldesleukin (BEMPEG; NKTR-214) efficacy as a single agent and in combination with checkpoint-inhibitor therapy in mouse models of osteosarcoma.
    Hennessy M; Wahba A; Felix K; Cabrera M; Segura MG; Kundra V; Ravoori MK; Stewart J; Kleinerman ES; Jensen VB; Gopalakrishnan V; Pena R; Quach P; Kim G; Kivimäe S; Madakamutil L; Overwijk WW; Zalevsky J; Gordon N
    Int J Cancer; 2021 Apr; 148(8):1928-1937. PubMed ID: 33152115
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Recruitment of host CD8+ T cells by tumor-infiltrating lymphocytes and recombinant interleukin-2 during adoptive immunotherapy of cancer.
    Burger UL; Chang MP; Goedegebuure PS; Eberlein TJ; Adams-Hodgins S
    Surgery; 1995 Mar; 117(3):325-33. PubMed ID: 7878540
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Caloric Restriction Impairs Regulatory T cells Within the Tumor Microenvironment After Radiation and Primes Effector T cells.
    Manukian G; Kivolowitz C; DeAngelis T; Shastri AA; Savage JE; Camphausen K; Rodeck U; Zarif JC; Simone NL
    Int J Radiat Oncol Biol Phys; 2021 Aug; 110(5):1341-1349. PubMed ID: 33647370
    [TBL] [Abstract][Full Text] [Related]  

  • 16. α-PD-L1 mAb enhances the abscopal effect of hypo-fractionated radiation by attenuating PD-L1 expression and inducing CD8
    Wang H; Lin X; Luo Y; Sun S; Tian X; Sun Y; Zhang S; Chen J; Zhang J; Liu X; Liu H; Gong Y; Xie C
    Immunotherapy; 2019 Feb; 11(2):101-118. PubMed ID: 30511887
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Intratumoral injection of interleukin-2 augments the local and abscopal effects of radiotherapy in murine rectal cancer.
    Yasuda K; Nirei T; Tsuno NH; Nagawa H; Kitayama J
    Cancer Sci; 2011 Jul; 102(7):1257-63. PubMed ID: 21443690
    [TBL] [Abstract][Full Text] [Related]  

  • 18. NKTR-255 is a polymer-conjugated IL-15 with unique mechanisms of action on T and natural killer cells.
    Robinson TO; Hegde SM; Chang A; Gangadharan A; Rivas S; Madakamutil L; Zalevsky J; Miyazaki T; Schluns KS
    J Clin Invest; 2021 Oct; 131(19):. PubMed ID: 34375310
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immunotherapy with anti-CD3 monoclonal antibodies and recombinant interleukin 2: stimulation of molecular programs of cytotoxic killer cells and induction of tumor regression.
    Nakajima F; Khanna A; Xu G; Lagman M; Haschemeyer R; Mouradian J; Wang JC; Stenzel KH; Rubin AL; Suthanthiran M
    Proc Natl Acad Sci U S A; 1994 Aug; 91(17):7889-93. PubMed ID: 8058730
    [TBL] [Abstract][Full Text] [Related]  

  • 20. High-dose per Fraction Radiotherapy Induces Both Antitumor Immunity and Immunosuppressive Responses in Prostate Tumors.
    Lin L; Kane N; Kobayashi N; Kono EA; Yamashiro JM; Nickols NG; Reiter RE
    Clin Cancer Res; 2021 Mar; 27(5):1505-1515. PubMed ID: 33219015
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 25.